- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00700739
Study to Investigate the Performance of Cervical Arthroplasty for the Treatment of Cervical Degenerative Disc Disease
September 2, 2015 updated by: DePuy International
A Multi-Centre, Prospective, Randomized, Post Marketing Surveillance Study Comparing Cervical Arthroplasty to Anterior Cervical Discectomy and Fusion (ACDF) for the Treatment of Cervical Degenerative Disc Disease
The purpose of the study is to evaluate the performance of the Discover cervical Artificial disc in the treatment of degenerative disc disease in one level of the cervical spine.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
The protocol underwent 3 amendments, the last of which (02APR2009) changed the study design from a randomized to a non-randomized and non-comparative clinical trial.
All of the subjects were enrolled under the randomized design with the exception of the last subject.
This study is not applicable per FDAA Title VIII, Section 801 due to the final trial design.
However, results are submitted to clinicaltrials.gov
due to the majority of study data being collected under a randomized (FDAA Title VIII, Section 801 applicable) trial design
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tasmania, Australia
- Calvary Hospital
-
-
New South Wales
-
Sydney, New South Wales, Australia
- Westmead Private Hospital
-
-
-
-
Holstein
-
Neustadt, Holstein, Germany
- Klinikum Neustadt
-
-
-
-
-
Rome, Italy
- Divisione di Neurochirurgia
-
-
-
-
-
Penang, Malaysia
- Island Hospital
-
-
-
-
-
Tilburg, Netherlands
- Elisabeth Ziekenhuis
-
-
-
-
-
Madrid, Spain
- La Paz Hospital
-
-
-
-
Lancashire
-
Manchester, Lancashire, United Kingdom
- Hope Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female subjects, aged between 18 and 65 years inclusive.
- Subjects who are able to give voluntary, written informed consent to participate in this clinical investigation and from whom consent has been obtained.
- Subjects who, in the opinion of the Clinical Investigator, are able to understand this clinical investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups.
Objective evidence of cervical disc disease in one vertebral level between C3-C7 defined as one or more of the following:
- Shoulder and/or arm pain in a radicular distribution resulting from herniated disc or bony osteophytes (Consistent w diagnostic imaging including Axial CT, CT Myelogram, MRI and/or plain films)
- Subjects with myeloradiculopathy resulting from mild spinal cord compression and nerve root impingement
- Unresponsive to documented non-surgical management for ≥ 6 weeks and/or presents with progressive symptoms of nerve root or spinal cord compression in the face of continued non-surgical management (e.g., physical therapy, medication therapy, corticosteroid injections, etc.)
- Minimum Neck Disability Index score of ≥30 % (15/50 points)
Exclusion Criteria:
- Subjects who, in the opinion of the Clinical Investigator, have an existing condition that would compromise their participation and follow-up in this clinical investigation.
- Subjects who are pregnant, lactating or wishes to become pregnant within the duration of the study.
- Subjects who are known drug or alcohol abusers or with psychological disorders that could affect follow-up care or treatment outcomes.
- Subjects who have participated in a clinical investigation with an investigational product in the last 30 days.
- Subjects who are currently involved in any injury litigation claims.
- Subjects with significant degeneration at more than one cervical level (e.g. DISH, ankylosing spondylitis, congenital abnormality, rheumatoid arthritis)
- Subjects who have had any prior surgery at the level to be treated (subjects with a prior Laminotomy at the level to be treated may be included in the study)
- Subjects who have marked cervical instability on lateral or flexion/extension x-rays defined as translation ≥3mm and/or ≥11 degrees of rotational difference to either adjacent level
- Subjects who have presence of systemic infection or infection at the site of surgery
- Subjects who have been diagnosed with malignancy
- Subjects who have been diagnosed with a condition or require postoperative medication(s) that may interfere with bony/soft tissue healing
- Subjects who have been diagnosed with Osteoporosis, Osteopenia, other metabolic bone disease or endocrine disorder known to affect osteogenesis.
- Subjects with pre-existing neurological abnormalities other than deficits produced from the spinal lesion (e.g., MS, Parkinson's, CVA, diabetic neuropathy, peripheral neuropathy).
- Subjects with morbid obesity defined as a BMI of ≥40, or more than 100 lbs (45.4kg) over ideal weight.
- Subjects with any known allergy to titanium metal, polyethylene, metal alloy or carbon fibre reinforced polymer
- Subjects who have had prior fusion surgery at any level(s) (C1-T1)
- Subjects with kyphosis >-15 degrees evaluated using the Cobb angle measurement
- Subjects with Significant cervical degenerative disease characterized by bridging anterior osteophytes, significant loss of disc space height (3mm or less), sclerotic facets, large posterior osteophytes, autofusion of other cervical levels, and degenerative retrolisthesis. Spinal diseases such as DISH, ankylosing spondylitis, congenital abnormality, and rheumatoid arthritis, should also be excluded
- Subjects undergoing treatment with a bone growth stimulator, which cannot be discontinued prior to enrollment in the study.
- Significant kyphotic deformity or significant reversal of lordosis.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Anterior Cervical Discectomy and Fusion (ACDF)
Anterior Cervical Discectomy and Fusion with Cervical CFRP I/F CAGE® and SLIM LOC(R) Anterior Cervical Plate System with allograft
|
Cervical CFRP I/F CAGE® and SLIM LOC(R) Anterior Cervical Plate System with allograft
|
|
Active Comparator: Cervical Total Disc Replacement
DISCOVER™ Artificial Cervical Disc
|
DISCOVER™ Artificial Cervical Disc
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall Patient Success
Time Frame: 12 months
|
Overall success was a composite endpoint determined by the following clinical outcome measures: 1. Neck Disability Index ≥ 15-point improvement from baseline to 12 months post-operative, 2. No new clinically significant permanent abnormalities in neurological function (i.e.
motor strength, nerve root tension signs, sensory and reflex signs) from baseline to 12 months post-operative, 3.
No subsequent secondary surgical interventions (SSI) at the index level, and 4. No device-related serious events (dSAE) from intra-operative through 12-months post-operative.
Please note that these time periods were intended to be from baseline to 24 months post-operative, but since the study was terminated early the 12 month time periods were utilized.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Visual Analogue Scale (VAS) Neck Pain From Pre-treatment to 12 Months
Time Frame: 12 months
|
The visual analogue scale (VAS) pain score asks the subject to place a vertical mark on a horizontal line (that is approximately 10 cm long) with 'No Pain' (score of 0 = 0 cm) listed on the left and 'Very severe pain' (score of 100 = 10 cm) labeled on the right.
The subject is instructed to indicate the amount of pain they feel in their neck.
|
12 months
|
|
Change in Visual Analogue Scale (VAS) Left Arm Pain From Pre-treatment to 12 Months.
Time Frame: 12 Months
|
The visual analogue scale (VAS) pain score asks the subject to place a vertical mark on a horizontal line (that is approximately 10 cm long) with 'No Pain' (score of 0 = 0 cm) listed on the left and 'Very severe pain' (score of 100 = 10 cm) labeled on the right.
The subject is instructed to indicate the amount of pain they feel in their left arm.
|
12 Months
|
|
Change in Visual Analogue Scale (VAS) Right Arm Pain From Pre-treatment to 12 Months.
Time Frame: 12 Months
|
The visual analogue scale (VAS) pain score asks the subject to place a vertical mark on a horizontal line (that is approximately 10 cm long) with 'No Pain' (score of 0= 0 cm) listed on the left and 'Very severe pain' (score of 100= 10 cm) labeled on the right.
The subject is instructed to indicate the amount of pain they feel in their right arm.
|
12 Months
|
|
Change in Visual Analogue Scale (VAS) Right Shoulder Pain From Pre-treatment to 12 Months.
Time Frame: 12 Months
|
The visual analogue scale (VAS) pain score asks the subject to place a vertical mark on a horizontal line (that is approximately 10 cm long) with 'No Pain' (score of 0 = 0 cm) listed on the left and 'Very severe pain' (score of 100 = 10 cm) labeled on the right.
The subject is instructed to indicate the amount of pain they feel in their right shoulder.
|
12 Months
|
|
Change in Visual Analogue Scale (VAS) Left Shoulder Pain From Pre-treatment to 12 Months.
Time Frame: 12 Months
|
The visual analogue scale (VAS) pain score asks the subject to place a vertical mark on a horizontal line (that is approximately 10 cm long) with 'No Pain' (score of 0 = 0 cm) listed on the left and 'Very severe pain' (score of 10 = 10 cm) labeled on the right.
The subject is instructed to indicate the amount of pain they feel in their left shoulder.
|
12 Months
|
|
Change in Mental Component Summary Quality of Life Measure Assessed by Short Form SF-36 From Pre-treatment to 12 Months
Time Frame: 12 months
|
The 36-item Short Form Health Survey (SF-36) is a patient reported outcome survey that evaluates functional health and well-being.
The survey is converted into 2 summary measures that are scored from 0 to 100 (where 100 indicates the highest level of health) - the Physical Component Score (PCS-36) and Mental Component Score (MCS-36)
|
12 months
|
|
Change in Physical Component Summary Quality of Life Measure Assessed by Short Form SF-36 From Pre-treatment to 12 Months
Time Frame: 12 months
|
The 36-item Short Form Health Survey (SF-36) is a patient reported outcome survey that evaluates functional health and well-being.
The survey is converted into 2 summary measures that are scored from 0 to 100 (where 100 indicates the highest level of health) - the Physical Component Score (PCS-36) and Mental Component Score (MCS-36)
|
12 months
|
|
Change in Function Assessed by Neck Disability Index Improvement From Pre-treatment to 12 Months
Time Frame: 12 months
|
The neck disability index (NDI) is a validated, disease specific, self-administrated questionnaire for assessing pain intensity and function in patients with neck pain on a scale from 0 to 100.
A lower score is a better result (i.e. less severe pain and/or better function).
The proportion of patients with an improved score (lower) of 15 points or more was the analysis variable.
|
12 months
|
|
Work Status Assessed at 12 Months
Time Frame: 12 months
|
The proportion of subjects with unrestricted work status (compared to subjects not working or with restricted work status) is reported at the 12 month follow-up interval.
|
12 months
|
|
Sagittal Angulation, Also Known as Global Lordosis, Measured Radiographically at 6 Months
Time Frame: 6 months
|
Sagittal Angulation is a measure of the angle formed between the inferior endplate of the C2 vertebrae and the corresponding inferior endplate of vertebrae C7 of the spine, measured in degrees, from a side (sagittal) view.
|
6 months
|
|
Adjacent Level Degeneration Measured Radiographically at 24 Months
Time Frame: 24 months
|
Adjacent Level Degeneration is evaluated using a point system that assigns numerical scores to severity of Height Loss, Anterior Osteophytes, and Endplate Sclerosis; and then grades into one of the following five categories: None, Mild, Moderate, Severe, or NA.
|
24 months
|
|
Maintenance of Disc Height Measured Radiographically at 6 Months
Time Frame: 6 months
|
Maintenance of disc height is measured at the index and adjacent levels to determine the effect of the treatment on restoration or maintenance of the disc height.
Initial post-operative disc height is compared with subsequent post-operative visits (i.e. 6 months) to evaluate the maintenance of disc height.
The height is measured in millimeters (mm).
|
6 months
|
|
Foraminal Height Measured Radiographically at 24 Months
Time Frame: 24 months
|
Foraminal height is the maximum vertical distance, measured in millimeters (mm), between the inferior surface of the superior pedicle and superior surface of the inferior pedicle.
These measurements are obtained via magnetic resonance imaging (MRI).
|
24 months
|
|
Cervical Range of Motion Measured Radiographically at 6 Months
Time Frame: 6 months
|
Cervical range of motion measures the angle, in degrees, between the inferior endplate of C2 to the inferior endplate of C7 on flexion-extension radiographs.
|
6 months
|
|
Device Related Adverse Events
Time Frame: Intra-operatively to 24 months post-operative
|
The proportion of subjects with device related adverse events as reported throughout the duration of the study.
|
Intra-operatively to 24 months post-operative
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2008
Primary Completion (Actual)
May 1, 2010
Study Completion (Actual)
May 1, 2010
Study Registration Dates
First Submitted
June 18, 2008
First Submitted That Met QC Criteria
June 18, 2008
First Posted (Estimate)
June 19, 2008
Study Record Updates
Last Update Posted (Estimate)
September 21, 2015
Last Update Submitted That Met QC Criteria
September 2, 2015
Last Verified
September 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CT 05/25
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.